The short version
Targeted Osmotic Lysis (TOL) is a published research concept. The hypothesis describes stimulating voltage-gated sodium channels that are more common on some solid tumor cells, while blocking sodium pumps, so that water balance in those cells is disrupted. It has been studied mainly in laboratory and veterinary settings.
TOL is investigational. It is not FDA-approved for any indication and is not available as a treatment through FixCancer.org. Safety and effectiveness in people are not established.
Where the evidence stands
- Most published evidence is preclinical or veterinary.
- Human evidence is limited to individual case reports, which cannot establish effectiveness.
- There are no published randomized trials of TOL.
For the full plain-language overview, read What is Targeted Osmotic Lysis? For labeled sources, see the literature stack.
Frequently asked questions
Is TOL FDA-approved?
No. Targeted Osmotic Lysis is investigational and is not FDA-approved for any indication.
Can I get TOL through FixCancer.org?
No. TOL is not available as a treatment through this site. We do not enroll, schedule, or provide therapy.
Has TOL been tested in people?
Human evidence is limited to individual case reports. There are no published randomized trials, and safety and effectiveness in people are not established.
Where should I start for care decisions?
With your licensed oncologist. Trusted sources include cancer.gov and ClinicalTrials.gov.
Still have TOL questions?
Send an education question through the contact form. This is not a clinic visit, not enrollment, and not a treatment offer.
Request a call / contact Read the literature stack